Search

Displaying results 711 - 720 of 10000 in total
  1. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [A189006] This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the … beginning of a new wave of treatment options for patients suffering from insomnia.

  2. Drug

    Amorolfine

    go.drugbank.com/drugs/DB09056
    ApprovedWithdrawn

    It is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries … It is not approved for the treatment of onychomycosis in the United States or Canada.

    Products: RAZOLE %0,25 KREM, 20 G, Amorocutan 50 mg/ml wirkstoffhaltiger Nagellack
  3. Drug

    Nifedipine

    go.drugbank.com/drugs/DB01115
    ApprovedInvestigational

    [A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383] … Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].

    Mixtures: NIF TEN 50, NIF-TEN CAPSULEProducts: Nu-nifedipine-PA, Nu-nifed Cap 10mg
  4. Drug

    Quinagolide

    go.drugbank.com/drugs/DB09097
    ApprovedWithdrawn

    Newer dopamine receptor agonists such as quinagolide and [DB00248] are shown to effectively inhibit prolactin secretion with improved efficacy over [DB01200]. … Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia.

    Synonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideProducts: Norprolac 0,025 mg u. 0,050 mg - Tabletten (Startpackung), NORPROLAC® 0.025 MG
  5. Drug

    Prasterone

    go.drugbank.com/drugs/DB01708
    ApprovedInvestigationalNutraceutical

    DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements. … In the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments.

    Categories: Sex Hormones and Modulators of the Genital System
  6. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    including biologics, or when the use of those therapies is inadvisable. … [L39774] The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases,

    Products: CIBINQO® 50 MG, CIBINQO® 200 MG
  7. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon- and ribavirin-based regimens, which were limited by infusion site reactions, reduced blood … Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [ribavirin] depending on the level of liver damage or cirrhosis [FDA Label].

    Mixtures: HARVONI 90 MG/400 MG FILM KAPLI TABLET, 84 ADET, HARVONI 90 MG/400 MG FILM KAPLI TABLET, 28 ADETCategories: Antivirals for treatment of HCV infections
  8. Drug

    AZD-8186

    go.drugbank.com/drugs/DB15029
    Investigational

    AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot

  9. Drug

    Pegcantratinib

    go.drugbank.com/drugs/DB16280
    Investigational

    Pegcantratinib is under investigation in clinical trial NCT03448081 (Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene).

  10. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    [A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage … It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma.

    Products: IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML, IMFINZI® 50 MG/ML CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN